de Moraes Daniel Clemente
Bolsista do Programa Pesquisa Produtividade UNESA, Rua Eduardo Luiz Gomes 134, Universidade Estácio de Sá, Centro, Niterói, RJ, Brazil CEP 24020-340.
J Mycol Med. 2022 Mar;32(1):101232. doi: 10.1016/j.mycmed.2021.101232. Epub 2021 Dec 1.
Candida auris emerges as an important causative agent of fungal infections, with worrisome mortality rates, mainly in immunocompromised individuals. This scenario is worsened by the limited availability of antifungal drugs and the increasing development of resistance to them. Due to the relevance of C. auris infections to public health, several studies aimed to discover new antifungal compounds capable of overcoming this fungus. Nonetheless, these information are decentralized, precluding the understandment of the current status of the search for new anti-C. auris compounds. Thus, this integrative review aimed to summarize information regarding anti-C. auris compounds reported in literature. After using predefined selection criteria, 71 articles were included in this review, and data from a total of 101 substances were extracted. Most of the studies tested synthetic substances, including several azoles. Moreover, drug repurposing emerges as a suitable strategy to discover new anti-C. auris agents. Few studies, however, assessed the mechanism of action and the in vivo antifungal activity of the compounds. Therefore, more studies must be performed to evaluate the usefulness of these substances as anti-C. auris therapies.
耳念珠菌已成为真菌感染的重要病原体,其死亡率令人担忧,主要发生在免疫功能低下的个体中。抗真菌药物的有限供应以及对这些药物耐药性的不断增加,使这种情况更加恶化。由于耳念珠菌感染对公共卫生的重要性,多项研究旨在发现能够攻克这种真菌的新型抗真菌化合物。然而,这些信息分散,妨碍了对新型抗耳念珠菌化合物研究现状的了解。因此,本综合综述旨在总结文献中报道的有关抗耳念珠菌化合物的信息。在使用预定义的选择标准后,本综述纳入了71篇文章,并提取了总共101种物质的数据。大多数研究测试的是合成物质,包括几种唑类。此外,药物再利用已成为发现新型抗耳念珠菌药物的合适策略。然而,很少有研究评估这些化合物的作用机制和体内抗真菌活性。因此,必须开展更多研究来评估这些物质作为抗耳念珠菌疗法的有效性。